Saad S. Kenderian

8.4k total citations · 2 hit papers
149 papers, 2.9k citations indexed

About

Saad S. Kenderian is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, Saad S. Kenderian has authored 149 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 61 papers in Genetics and 34 papers in Immunology. Recurrent topics in Saad S. Kenderian's work include CAR-T cell therapy research (86 papers), Chronic Lymphocytic Leukemia Research (55 papers) and Lymphoma Diagnosis and Treatment (26 papers). Saad S. Kenderian is often cited by papers focused on CAR-T cell therapy research (86 papers), Chronic Lymphocytic Leukemia Research (55 papers) and Lymphoma Diagnosis and Treatment (26 papers). Saad S. Kenderian collaborates with scholars based in United States, Italy and China. Saad S. Kenderian's co-authors include Elizabeth L. Siegler, Marco Ruella, Saar Gill, Carl H. June, Olga Shestova, Reona Sakemura, Michael Klichinsky, Martin Carroll, Jennifer J.D. Morrissette and Olivia Sirpilla and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Saad S. Kenderian

138 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities

2022 169 citations Elizabeth L. Siegler, Saad S. Kenderian et al. profile →
CAR-T Cell Therapy: the Efficacy and Toxicity Balance

2023 98 citations Elizabeth L. Siegler, Saad S. Kenderian et al. profile →

Peers

Countries citing papers authored by Saad S. Kenderian

Since Specialization

Citations

This map shows the geographic impact of Saad S. Kenderian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saad S. Kenderian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saad S. Kenderian more than expected).

Fields of papers citing papers by Saad S. Kenderian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saad S. Kenderian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saad S. Kenderian. The network helps show where Saad S. Kenderian may publish in the future.

Co-authorship network of co-authors of Saad S. Kenderian

This figure shows the co-authorship network connecting the top 25 collaborators of Saad S. Kenderian. A scholar is included among the top collaborators of Saad S. Kenderian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saad S. Kenderian. Saad S. Kenderian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Pleiotropic Roles of Cytokines in Chimeric Antigen Receptor T-cell Therapy 2025 ·Cancer Immunology Research ·(unknown), Elizabeth L. Siegler, Saad S. Kenderian	0
2	ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia 2025 ·PubMed ·Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B. Maris, Paolo Ghia, Michael Byrne, Nancy L. Bartlett, John M. Pagel, Yan Zheng, (unknown), Wangshu Zhang, (unknown), Javier Pinilla‐Ibarz	2
3	Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria 2025 ·American Journal of Hematology ·(unknown), Meera Sridharan, Ronald S. Go, Ann M. Moyer, Nelson Leung, Maria Alice V. Willrich, Robert Christian Wolf, (unknown), (unknown), (unknown), Urshila Durani, Aasiya Matin, Mehrdad Hefazi, Saad S. Kenderian, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mark R. Litzow, William J. Hogan, David Dingli, Hassan B. Alkhateeb	3
4	Chronic Lymphocytic Leukemia Infiltrating in the Brain 2024 ·Cureus ·(unknown), Saad S. Kenderian, Alberto Angeli, Matthew T. Howard, Eelco F. M. Wijdicks	0
5	Metformin and cytokine release syndrome after immune effector cell therapy. 2024 ·Journal of Clinical Oncology ·(unknown), Radhika Bansal, Hassan B. Alkhateeb, Stephen M. Ansell, (unknown), Moritz Binder, Joselle Cook, Urshila Durani, Morie A. Gertz, Paul J. Hampel, Suzanne R. Hayman, Patrick B. Johnston, Prashant Kapoor, Saad S. Kenderian, Arushi Khurana, Shaji Kumar, Taxiarchis Kourelis, (unknown), Jonas Paludo, David Dingli	0
6	CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, (unknown), (unknown), (unknown), Serena Perna, Sherilyn A. Tuazon, San‐San Ou, Sahar Ansari, (unknown), (unknown), Revathi Ananthakrishnan, (unknown), Leanne Peiser, Tanya Siddiqi	3
7	Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, (unknown), Pradipta Ray, (unknown), Serena Perna, Sherilyn A. Tuazon, (unknown), Sahar Ansari, (unknown), (unknown), Revathi Ananthakrishnan, (unknown), Leanne Peiser, Tanya Siddiqi	1
8	Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy 2024 ·Blood ·Radhika Bansal, (unknown), Monica Shaw, (unknown), (unknown), (unknown), Arushi Khurana, Paul J. Hampel, Urshila Durani, Suzanne R. Hayman, Yucai Wang, Moritz Binder, Jonas Paludo, Saad S. Kenderian, N. Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, (unknown)	1
9	Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer 2023 ·Surgery ·(unknown), Jason Whitt, Hailey Houson, (unknown), Rachael Guenter, Tejeshwar C. Rao, Dezhi Wang, (unknown), (unknown), (unknown), Andrea Gillis, Herbert Chen, John A. Copland, Saad S. Kenderian, Ricardo V. Lloyd, Mariusz W. Szkudlinski, Suzanne E. Lapi, Renata Jaskula‐Sztul	10
10	Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy 2022 ·Transplantation and Cellular Therapy ·Miguel‐Angel Perales, Larry D. Anderson, Tania Jain, Saad S. Kenderian, Olalekan O. Oluwole, Gunjan L. Shah, Jakub Svoboda, Mehdi Hamadani	24
11	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL 2021 ·Blood ·Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, José F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt	23
12	Omics analyses provide insights to CART cell therapy resistance 2021 ·Michelle J. Cox, Saad S. Kenderian	0
13	Gene Editing and Gene Therapy: Entering Uncharted Territory in Veterinary Oncology 2021 ·Preprints.org ·Wesley A. Wierson, Alex Abel, Elizabeth L. Siegler, Stephen C. Ekker, Chad M. Johannes, Saad S. Kenderian, Jonathan P. Mochel	1
14	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells 2020 ·Clinical Cancer Research ·(unknown), (unknown), Rondell P. Graham, Nathan W. Cummins, (unknown), Enrique Garcia-Rivera, J. Anderson, Sekar Natesampillai, (unknown), (unknown), Zilin Nie, Thomas D.Y. Chung, Richard Buick, Andrew L. Feldman, Rebecca L. King, Anne J. Novak, Stephen M. Ansell, Saad S. Kenderian, Andrew D. Badley	5
15	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy 2020 ·SHILAP Revista de lepidopterología ·Rosalie M. Sterner, Karen E. Hedin, Richard E. Hayden, Grzegorz S. Nowakowski, Saranya P. Wyles, Alexandra J. Greenberg, André Terzic, Saad S. Kenderian	13
16	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice 2020 ·Cancer Medicine ·Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, José F. Leis, Saad S. Kenderian, Asher Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie Fonder, Kristen McCullough, (unknown), Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt	39
17	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells 2017 ·Cancer Discovery ·Marco Ruella, Michael Klichinsky, Saad S. Kenderian, Olga Shestova, Amy Ziober, (unknown), Michael D. Feldman, Mariusz A. Wasik, Carl H. June, Saar Gill	153
18	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma 2016 ·Clinical Cancer Research ·Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nuñez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael C. Milone, Simon F. Lacey, Anthony R. Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik	141
19	Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms 2016 ·Blood ·Marco Ruella, Saad S. Kenderian, Olga Shestova, Michael Klichinsky, J. Joseph Melenhorst, Mariusz A. Wasik, Simon F. Lacey, Carl H. June, Saar Gill	8
20	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model 2016 ·Blood ·Saad S. Kenderian, Marco Ruella, Olga Shestova, Miriam Kim, Michael Klichinsky, Fang Chen, (unknown), Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact